Published in Crit Rev Oncol Hematol on February 01, 2005
Voluntary medical male circumcision: modeling the impact and cost of expanding male circumcision for HIV prevention in eastern and southern Africa. PLoS Med (2011) 7.56
A model for the roll-out of comprehensive adult male circumcision services in African low-income settings of high HIV incidence: the ANRS 12126 Bophelo Pele Project. PLoS Med (2010) 2.43
Prevalence of human papillomavirus in penile malignant tumors: viral genotyping and clinical aspects. BMC Urol (2015) 0.84
Penile cancer disparities in Puerto Rican men as compared to the United States population. Int Braz J Urol (2013) 0.84
Imaging in primary penile cancer: current status and future directions. Eur Radiol (2009) 0.81
Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases. Hum Pathol (2015) 0.78
Endoscopic inguinal lymph node dissection for penile carcinoma: the developing of a novel technique. World J Urol (2009) 0.78
A review of penile cancer. Adv Urol (2010) 0.77
Epigenetic mechanisms in penile carcinoma. Int J Mol Sci (2013) 0.77
Destructive squamous cell carcinoma of the penis. Am J Med Sci (2015) 0.75
Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol (2007) 8.05
Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol (2008) 7.18
Gastric cancer. Crit Rev Oncol Hematol (2009) 2.87
Incidence of uveal melanoma in Europe. Ophthalmology (2007) 2.30
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol (2011) 1.99
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
Major and minor salivary gland tumors. Crit Rev Oncol Hematol (2009) 1.77
Ovarian cancer. Crit Rev Oncol Hematol (2006) 1.64
Colon cancer. Crit Rev Oncol Hematol (2010) 1.62
Cholangiocarcinoma. Crit Rev Oncol Hematol (2008) 1.59
Glioblastoma in adults. Crit Rev Oncol Hematol (2008) 1.54
Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: a study from the Programma Ricerca e Innovazione Emilia Romagna Oncology Research Group. J Clin Oncol (2008) 1.46
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer (2006) 1.41
Ependymoma. Crit Rev Oncol Hematol (2007) 1.41
[Update on anticancer drugs]. Assist Inferm Ric (2014) 1.38
Germ cell tumours of the testis. Crit Rev Oncol Hematol (2005) 1.37
Adult acute myeloid leukaemia. Crit Rev Oncol Hematol (2004) 1.37
The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer (2005) 1.36
Long-term survival expectations of cancer patients in Europe in 2000-2002. Eur J Cancer (2008) 1.35
Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes (2003) 1.34
Cancer of the prostate. Crit Rev Oncol Hematol (2005) 1.31
The cure of cancer: a European perspective. Eur J Cancer (2009) 1.31
Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer (2010) 1.26
Cancer of the larynx. Crit Rev Oncol Hematol (2003) 1.19
Incidence of and survival from Wilms' tumour in adults in Europe: data from the EUROCARE study. Eur J Cancer (2006) 1.18
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer (2009) 1.17
Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hematol (2004) 1.17
Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol (2007) 1.17
Gastric cancer. Crit Rev Oncol Hematol (2005) 1.16
Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. J Urol (2010) 1.16
The burden of rare cancers in Italy: the surveillance of rare cancers in Italy (RITA) project. Tumori (2012) 1.15
Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int (2010) 1.13
Survival in patients with uveal melanoma in Europe. Arch Ophthalmol (2008) 1.11
Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open (2013) 1.10
Survival from salivary glands adenoid cystic carcinoma in European populations. Oral Oncol (2008) 1.08
Chemotherapy in patients with teratoma with malignant transformation. Eur Urol (2006) 1.03
Oligodendroglioma. Crit Rev Oncol Hematol (2008) 1.01
'Burned-out' primary testicular cancer. BJU Int (2004) 1.01
Explaining gastric cancer survival differences among European countries. Int J Cancer (2004) 1.00
Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Crit Rev Oncol Hematol (2009) 0.99
Cancer of the nasopharynx. Crit Rev Oncol Hematol (2003) 0.97
Renal cancer. Crit Rev Oncol Hematol (2007) 0.96
Childhood medulloblastoma. Crit Rev Oncol Hematol (2010) 0.92
Human papillomavirus in HNSCC: a European epidemiologic perspective. Hematol Oncol Clin North Am (2008) 0.92
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol (2009) 0.90
Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer (2004) 0.90
Colon cancer. Crit Rev Oncol Hematol (2004) 0.89
Mixed nonseminomatous germ cell tumor presenting as a subcutaneous tissue mass. Am J Dermatopathol (2006) 0.88
Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology (2010) 0.87
Prevalence and treatment of cancer pain in Italian oncological wards centres: a cross-sectional survey. Support Care Cancer (2008) 0.86
Comparing cancer care, outcomes, and costs across health systems: charting the course. J Natl Cancer Inst Monogr (2013) 0.86
Germ cell tumors. Case 3. Primary yolk sac tumor of the liver. J Clin Oncol (2004) 0.86
Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. Support Care Cancer (2010) 0.86
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Eur J Cancer (2011) 0.85
Rectal cancer. Crit Rev Oncol Hematol (2008) 0.84
Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer (2010) 0.83
Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. Support Care Cancer (2004) 0.83
Treatment of lung cancer. N Engl J Med (2009) 0.82
Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis. Crit Rev Oncol Hematol (2013) 0.82
Evidence-based recommendations for the use of antiemetics in radiotherapy. Radiother Oncol (2005) 0.82
Is there still a role for the uniscale assessment of quality of life? Tumori (2007) 0.82
[Urothelial tumors]. Prog Urol (2007) 0.81
International collaborations in cancer control and the Third International Cancer Control Congress. Tumori (2009) 0.81
[Cost analysis of tumor-induced osteolysis treated with intravenous zoledronic acid and pamidronate: a time-motion study]. Recenti Prog Med (2007) 0.81
Perivesical fat invasion in bladder cancer: implications for prognosis comparing pT2b, pT3a and pT3b stages and consequences for adjuvant chemotherapy indications. BJU Int (2012) 0.80
Bladder cancer. Crit Rev Oncol Hematol (2002) 0.80
Rectal cancer. Crit Rev Oncol Hematol (2004) 0.80
Estimates of cancer burden in Italy. Tumori (2013) 0.80
Cancer burden estimates and forecasts: uses and cautions. Tumori (2013) 0.80
The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants. Support Care Cancer (2004) 0.79
Management of adults with Wilms' tumor: recommendations based on international consensus. Expert Rev Anticancer Ther (2011) 0.79
Bladder-conserving surgery and interstitial brachytherapy for lymph node negative transitional cell carcinoma of the urinary bladder: results of a 28-year single institution experience. Radiother Oncol (2004) 0.77
Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB). Oncology (2013) 0.77
The cost of chemotherapy-induced nausea and vomiting in Italy. Support Care Cancer (2006) 0.77
Regional estimates of prostate cancer burden in Italy. Tumori (2007) 0.77
Uncommon malignancies: case 3. Paratesticular desmoplastic small round-cell tumor. J Clin Oncol (2005) 0.77
Cancer of pancreas. Crit Rev Oncol Hematol (2004) 0.76
Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project. Cancer Epidemiol (2013) 0.76
Cetuximab for colorectal cancer. N Engl J Med (2008) 0.75
Tackling off-label use of anticancer drugs. J Clin Oncol (2012) 0.75
Cetuximab for metastatic colorectal cancer. N Engl J Med (2009) 0.75
Do we need new antiemetic guidelines? Support Care Cancer (2002) 0.75
Estimates of cancer burden in Veneto. Tumori (2013) 0.75
Germ cell tumors. Case 2. Unusual course of pure testicular seminoma. J Clin Oncol (2004) 0.75
Antiemetic therapy. Crit Rev Oncol Hematol (2002) 0.75
[Urothelial tumors]. Prog Urol (2004) 0.75
FDG PET/CT findings in secondary hyperparathyroidism not mimicking multiple bone metastases. Eur J Nucl Med Mol Imaging (2008) 0.75
[Upper urinary tract tumor: conservative treatment of localized forms]. Prog Urol (2003) 0.75
[Methodology of drug utilization studies]. Suppl Tumori (2004) 0.75
[Case-control evaluation of screening efficacy]. Epidemiol Prev (2005) 0.75
Inappropriate doses of chemotherapy in Italian breast cancer patients enrolled in clinical trials. Tumori (2008) 0.75
[Cancer-related fatigue]. Recenti Prog Med (2015) 0.75
Surgical treatment of primitive thyroid lymphoma. Tumori (2010) 0.75
Estimates of cancer burden in Puglia. Tumori (2013) 0.75
[Follow-up of urothelial tumours. Guidelines of the Comité de Cancérologie de l'Association Française d'Urologie]. Prog Urol (2005) 0.75
Multinational Association of Supportive Cancer Care (MASCC). Support Care Cancer (2003) 0.75